Salud Pública de México

Historical distribution of central nervous system tumors in the Mexican National Institute of Neurology and Neurosurgery

Historical distribution of central nervous system tumors in the Mexican National Institute of Neurology and Neurosurgery

Lucinda Aguirre-Cruz, PhD,(1,2) Edgar Rangel-López, PhD,(2) Dora Luz de la Cruz-Aguilera, PhD,(2) Citlali Ekaterina Rodríguez-Pérez, PhD,(2) Luis Ruano, MD,(3) Leora Velásquez-Pérez, MSc,(4) Mauricio Martínez-Moreno, MD,(1) Juan Garduño-Espinosa, MD,(5) Julio Sotelo, PhD.(1)

(1) Laboratorio de Inmunología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Ciudad de México, México.

(2) Laboratorio de Neuroimmunoendocrinología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Ciudad de México, México.

(3) Consulta Externa, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Ciudad de México, México.

(4) Departamento de Epidemiología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Ciudad de México, México.

(5) Subdirección de Investigación, Hospital Infantil de México Federico Gómez. Ciudad de México, México.


Objective. To determine the frequency of central nervous system (CNS) tumors in the first fifty years of the National Institute of Neurology and Neurosurgery of Mexico Manuel Velasco Suárez (Instituto Nacional de Neurología y Neurocirugía de México, INNN) from 1965 to 2014. Materials and methods. A total of 16 116 institutional records of CNS tumors were analyzed. The frequency and distribution of CNS tumors were evaluated by tumor type, patient age and patient gender. The annual relationship between CNS tumors and surgical discharges (SD) over the last 20 years was estimated. Results. The frequencies of most CNS tumors were consistent with those found worldwide, and the most common tumors were neuroepithelial tumors (33%), particularly astrocytic tumors (67%); meningeal tumors (26%); and pituitary tumors (20%). The incidence of pituitary tumors in these data was twice as high as that reported in other regions of the world, and the relationship between CNS tumors and SD was consistent over time (0.22-0.39). Conclusion. This study summarizes the largest sample of CNS tumor cases analyzed in Mexico and provides an important reference of the frequency of this tumor type in the country. This work will serve as a basis for conducting studies evaluating factors associated with the presence of CNS tumors and for identifying adequate public health interventions.

Keywords: central nervous system neoplasms; astrocytoma; meningioma; pituitary neoplasms; Mexico


Objetivo. Determinar la frecuencia de neoplasias del sistema nervioso central (NSNC) en los primeros 50 años del Instituto Nacional de Neurología y Neurocirugía de México (INNN). Material y métodos. Se analizaron 16 116 registros institucionales de las NSNC, atendidas en el INNN de 1965 a 2014; se estimó su frecuencia y distribución por tipo de neoplasia, edad y género, y se determinó la relación anual de NSNC y egresos quirúrgicos (EQ) en un período de 20 años. Resultados. Las frecuencias de la mayoría de NSNC fueron consistentes con las encontradas a nivel mundial. Las más frecuentes fueron las neuroepiteliales (33%), entre las cuales destacaron las astrocíticas (67%); meníngeas (26%), e hipofisiarias (20%). El número de neoplasias hipofisiarias en esta serie fue dos veces mayor al reportado en otras regiones del mundo y la relación NSNC/EQ fue similar a través del tiempo (0.22-0.39). Conclusión. Ésta es la mayor serie de casos de NSNC analizados en México y proporciona un referente importante sobre la frecuencia de este tipo de neoplasias en el país. Este trabajo servirá de base para llevar a cabo estudios de los factores asociados a la presencia de NSNC e identificar intervenciones de salud pública adecuadas.

Palabras clave: neoplasias del sistema nervioso central; astrocitoma; meningioma; neoplasias hipofisiarias; México

Central nervous system (CNS) tumors in adults are the tenth leading cause of estimated new cancer cases and the twelfth leading cause of death worldwide,1 with an estimated 22 850 new cases and 15 320 deaths in 2015.2 In the United States, CNS tumors contribute to one of the highest cancer incidence rates.3 Their degree of malignancy is variable, and although some tumors are classified as benign, the majority are often lethal due to their capacity to infiltrate tissues and to cause malignant transformation over time,4 causing progressive neurological deficit, motor skill loss, headaches, mental impairment and seizures.5-8

In Mexico, the epidemiology of CNS tumors is uncertain, as the majority of studies evaluating their frequency include a limited number of cases or focus on specific types of tumors.9,10 As a result, these cases are not representative of the general population, which makes comparisons with international epidemiological studies difficult. Various studies that describe the frequency of CNS tumors in various hospital settings throughout the country exist, with results published in regional journals. However, they do not provide a comprehensive epidemiological understanding of these tumors. Two prior studies on CNS tumor frequency were conducted in the National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico (Instituto Nacional de Neurología y Neurocirugía de México, INNN).9,11 However, neither of these studies analyzed study periods that were as long as that evaluated in the present study. The 1997 Mohar and colleagues study on the distribution of malignant tumors seen in the Mexican National Cancer Institute from 1985 to 1994 reported that nervous system tumors were the 13th most common cancer.12 However, in Mexico, these tumors caused 2.6% of cancer-associated deaths in 200013 and were the leading cause of head and neck cancer deaths.14

The exact frequency, age and gender distribution, as well as trends in CNS tumors, in Mexico are unknown. This lack of information makes it difficult to provide inferences about the etiology, the associated risk factors and the magnitude of the health problem that these diseases cause for the purpose of establishing appropriate public health strategies.

The present study analyzes a large number of CNS tumor cases over a period of fifty years in the INNN, a reference hospital center in Mexico where this type of cancer is one of the leading causes of morbidity and mortality.15 Here, we describe the types of CNS tumors and the age and gender distributions of patients with CNS tumors and estimate their relationship with surgical discharges over the last 20 years to understand trends in this cancer over time.

Materials and methods

Study design

This was a descriptive and retrospective study. Data on CNS tumor frequency were obtained from records from 1965 to 2014 that existed in the clinical records of the Pathology, Neurosurgery and Epidemiology Departments (files) of the INNN. These records contained information on patients’ demographics, histological diagnosis and clinical characteristics, and the consistency of information contained within them was corroborated.

CNS tumors were grouped based on the existing international classifications from 1965 to 2014, as follows: 1) Bailey and Cushing16 (from 1965 to 1978), which included tumor histogenesis and took into account tumor types, such as medulloblastoma, astroblastoma, ependymoma and spongioblastoma (subsequently referred to as glioblastoma multiforme); 2) Zülch17 (from 1979 to 1992), whose grouping considered criteria related to the prognostic evaluation of cases; and Kleihues and colleagues18 (from 1993 to 2014), a categorization that introduced immunohistochemistry into the diagnosis and in which the tumor types identified by Bailey and Cushing as gliomas were distributed into specific groups. CNS tumors were identified based on the 2007 World Health Organization (WHO) classification of tumors of the central nervous system,19 except for gliomas, pituitary adenomas (which are currently considered in an independent classification) and metastatic tumors.

Men and women aged 15 to 96 years with a confirmed histopathological diagnosis of CNS tumor who had a complete clinical record were included in the study. Cases of patients with recurrent cancer were excluded.

The INNN Research and Ethics Committee approved the present study. The data obtained from clinical files were treated with utmost confidentiality, preserving the patients’ right to privacy.

Statistical analysis

CNS tumors identified between 1965 and 2014 were grouped according to the 2007 WHO classification of CNS tumors, and their relative frequencies were determined. Subsequently, CNS tumor frequencies were analyzed in three periods, according to classifications used from 1965 to 2014, and the percentages were compared using the Chi square test to identify differences between the proportions.

The distribution of CNS tumors was described by both gender and age quintiles from 15 to 79 years, including an extra category for subjects aged 80 years and older. Age group stratification was created using equidistant categories,20 which included the wide spectrum of ages at tumor presentation. The incidence rate of tumors of neuroepithelial tissue from 1995 to 2014 was analyzed, and the annual proportions of CNS tumors and overall surgical discharges (CNS tumors/SD) and their 95% confidence intervals were arbitrarily calculated from 1995 to 2014 using surgical discharge records dating back to 1995. This information was coded and included in a database for analysis using the Statistical Package for the Social Sciences (SPSS version 20, IBM Corp. Armonk, NY).(a)


Between 1965 to 2014, 16 116 patients with CNS tumors were treated in the INNN. However, 3 320 of those patients had recurrent tumors, an uncertain diagnosis or an incomplete clinical record and were excluded from the study.

The most common CNS tumors were tumors of neuroepithelial tissue, followed by meningeal and pituitary tumors (figure 1). In the period from 1995 to 2014, the most common tumors of neuroepithelial tissue were astrocytomas (table I). With regard to age, neuroepithelial tissue, meningeal, pituitary, cranial nerve and lymphoid CNS tumors were the most common tumor types in the third and fourth decades of life, while germ cell and sellar region tumors were the most common tumor types in the second decade (figure 2).



The frequency of CNS tumors was similar with regard to gender (women, n=6 633, 52.6%; men, n=5977, 47.4%). However, there was an indication of gender predominance with specific tumors, including germ cell and neuroepithelial tissue tumors, which were more common in men than in women, while meningeal tumors were more common in women than in men (figure 2).


Throughout the periods 1965-1978, 1979-1992 and 1993-2014, there was an increase in the number of CNS tumors treated at the INNN (876, 2915, and 9005, respectively). With regard to the distribution of the main types of CNS tumors, statistically significant differences were observed in the three study periods (p < 0.001). The number of tumors in the “other” category decreased between the first (6.5%) and third (0.75%) periods (table II).


The annual CNS tumors/SD relationship calculated to compare the trend in tumor numbers was similar in the 1995-2014 period (0.22-0.39), although increases in the ratio were observed in two periods (one between 2000 and 2002 and the other between 2004 and 2008) (figure 3).



The cases reported here represent the largest sample of CNS tumors analyzed in Mexico.

The number of CNS tumors seen in the INNN increased over time, although the CNS tumors/SD relationship did not considerably vary (figure 3). However, this increase does not necessarily reflect an increase in the incidence of CNS tumors in the general Mexican population, as this trend could be associated with a gradual increase in the number of patients treated at the institute, which is the largest national reference center for patients with neurological conditions.21,22 Other factors, including the introduction of innovative diagnostic technologies in the 1970s and 1980s using computerized axial tomography and magnetic resonance23-25 and improvements in histopathological diagnosis and recording methods, could also explain the increase.26,27

The frequencies of neuroepithelial tissue and meningeal tumors were similar to those reported in other countries.28-31 However, the frequency of pituitary tumors in this study (20%) was two times higher than that reported in Austria, the United States and Egypt, where this tumor represented 8.9, 9.1 and 11% of CNS tumors, respectively.32-34 This fact could be associated with ethnic factors,35,36 geographical distribution37 and other risk factors.38-40

The high frequency of germ cell tumors in the second decade of life was similar to that found in other studies.41-43 In turn, sellar region tumors occurred in patients at younger ages than have been reported in other studies.44,45

In general, CNS tumors were most often noted in women, a finding that has also been reported by other groups.46,47 The predominance of germ cell and neuroepithelial tissue tumors in men and meningeal tumors in women agrees with results that have been previously reported.48,49 This gender predominance could be attributed to sex hormones and genetic differences between men and women.50

The differences in the distribution of CNS tumors in the three study periods are likely related to the lack of inclusion of lymphoma cases in the first two periods. The decrease in the frequency of tumors classified as “others” reflects a better categorization and knowledge of these tumors (table II).

In general, the low variability with regard to CNS tumors/SD from 1995 to 2014 suggests that the number of CNS tumor cases has not increased in recent years. However, it is necessary to conduct multicenter epidemiological studies that are representative of the Mexican population and that would allow for the incidence rates of these diseases to be determined.

The primary limitation of the present study is that its results cannot be extrapolated to the general Mexican population, in spite of the fact that the included patients come from various parts of the country. However, our results are noteworthy because the INNN is a neurological reference center in which 90 000 consultations are made yearly,21 yielding a large number of CNS tumor cases, which is the first or second leading cause of morbidity and mortality in this population.15

Our results reflect the technical and caregiving capacity of the INNN with respect to CNS tumors and contribute to the evidence regarding the frequency of CNS tumors in developing countries and in other similar hospital centers worldwide. Future studies regarding factors associated with CNS tumor development should be conducted in Mexico.


Thanks to the Clinical Records, Pathology, Neurosurgery and Epidemiology Departments, to the Mexican Council for Science and Technology for the grant awarded to Mauricio Martínez Moreno, and to Dr. Isaac Acosta Castillo for his help in the statistical analysis of the results.

Declaration of conflict of interests. The authors declare that they have no conflict of interests.


(a) IBM SPSS Statistics for Windows 20.0.


1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.

2. American Cancer Society. Cancer facts and figures 2015. Atlanta, Ga: American Cancer Society, 2015.

3. Gittleman HR1, Ostrom QT, Rouse CD, Dowling JA, de Blank PM, Kruchko CA, et al. Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 2015;121(1):102-112.

4. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2012;379(9830):1984-1996

5. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002;4:278-299.

6. McKinney PA. Brain tumours: incidence, survival, and aetiology. J Neurol Neurosurg Psychiatr 2004;75(Suppl 2):ii12-ii17.

7. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin 2007;25(4):867-890.

8. Huttner A. Overview of primary brain tumors: pathologic classification, epidemiology, molecular biology, and prognostic markers. Hematol Oncol Clin North Am 2012;26(4):715-732.

9. Velásquez-Pérez L, Jiménez-Marcial ME, Martínez-Martínez JE. Epidemiology of central nervous system tumors at the Instituto Nacional de Neurología y Neurocirugía in Mexico city. Neurologia 2004;19(8):407-413.

10. Calderón-Garcidueñas AL, Pacheco-Calleros J, Castelán-Maldonado E, Nocedal-Rustrián FC. Linfoma primario del sistema nervioso central: experiencia de 20 años en un hospital de referencia. Rev Neurol 2008;46(2):84-88.

11. López-González MA, Sotelo J. Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Neoplasm 2000;53:157-162.

12. Mohar A, Frías-Mendivil M, Suchil-Bernal L, Mora-Macias T, de la Garza JG. Descriptive epidemiology cancer in the National Cancer Institute of Mexico. Salud Publica Mex 1997;39:253-258.

13. Secretaría de Salud; Dirección General de Epidemiología. Compendio de Cáncer, Mortalidad/Morbilidad. Registro histopatológico de neoplasias malignas. Distrito Federal: Secretaría de Salud, 2000.

14. Tirado L, Granados M. Epidemiología y etiología del cáncer de la cabeza y el cuello. En: Mohar A. (ed). Registro Histopatológico de Neoplasias. México: Instituto Nacional de Cancerología, 2007.

15. Velásquez-Pérez L, Núñez-Santes A, Contreras-Cortés GA. Overview of hospital mortality at the National Institute of Neurology and Neurosurgery of Mexico City. Gac Med Mex 2009;145(5):369-374.

16. Bailey P, Cushing HW. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis. Philadelphia, PA: J. B. Lippincott, 1926.

17. Zülch KJ. Histological typing of tumours of the central nervous system. Geneva: World Health Organization, 1979.

18. Kleihues P, Burger PC, Scheithauer BW (eds). Histological typing of tumours of the central nervous system. World Health Organization international histological classification of tumours. Heidelberg: Springer, 1993.

19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of tumours of the central nervous system. Lyon: IARC, 2007.

20. Choi BCK, de Guia NA, Walsh P. Look before you leap: stratify before you standardize. Am J Epidemiol 1999;149:1087-1096.

21. Secretaría de Salud. Comisión Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta Especialidad. Informe de actividades 2010-2012. México: Secretaría de Salud, 2012.

22. Celis MA. Medicina. In: Arriaga-Mendicoa N, comp. México: Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, 2014.

23. Coleman L. Magnetic resonance imaging of the supratentorial brain. Geisinger Bull 1987;36:33-40.

24. Rodríguez-Carbajal J. Ciencia y Tecnología en el Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez: el cerebro en imágenes. In: Flores-Rodríguez T, Gómez-Aviña A, Sotelo-Morales J, Torres-Ruiz A (eds.): Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez: 30 años de historia 1964-1994. Distrito Federal: Conacyt, 1994:123-133.

25. Helseth A. The incidence of primary central nervous system neoplasms before and after computerized tomography availability. J Neurosurg 1995;83:999-1003.

26. Davis FG, Bruner JM, Surawicz TS. The rationale for standardized registration and reporting of brain and central nervous system tumors in population-based cancer registries. Neuroepidemiol 1997;16:308-316.

27. Ausman JI. Watch out! The electronic age in medicine is here. Surg Neurology 2008;70:221-222.

28. Materljan E, Materljan B, Sepcić J, Tuskan-Mohar L, Zamolo G, Erman-Baldini I. Epidemiology of central nervous system tumors in Labin area, Croatia, 1974-2001. Croat Med J 2004;45:505-506.

29. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 2010;12:520-527.

30. Aryal G. Histopathological pattern of central nervous system tumor: A three year retrospective study. J Pathol Nepal 2011;1:22-25.

31. Ahsan J, Hashmi SN, Muhammad I, Din HU, Butt AM, Nazir S, Azhar M. Spectrum of Central Nervous System tumours-A single centre histopathological review of 761 cases over 5 years. J Ayub Med Coll Abbottabad 2015;27(1):81-84.

32. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009;95(3):401-411.

33. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1999;1(1):14-25.

34. Zalata KR, El-Tantawy DA, Abdel-Aziz A, Ibraheim AW, Halaka AH, Gawish HH, et al. Frequency of central nervous system tumors in delta region, Egypt. Indian J Pathol Microbiol 2011;54(2):299-306.

35. McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA. Demographic differences in incidence for pituitary adenoma. Pituitary 2011;14(1):23-30.

36. Karavitaki N. Prevalence and incidence of pituitary adenomas. Ann Endocrinol (Paris) 2012;73(2):79-80.

37. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010;72(3):377-382.

38. Schoemaker MJ, Swerdlow AJ. Risk factors for pituitary tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 2009;18(5):1492-1500.

39. Vasilev V, Daly A, Naves L, Zacharieva S, Beckers A. Clinical and genetic aspects of familial isolated pituitary adenomas. Clinics (Sao Paulo) 2012;67(Suppl 1):37-41.

40. Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O,

Rosén T, Filipsson-Nyström H. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol 2014;171(4):519-526.

41. Suh YL, Koo H, Kim TS, Chi JG, Park SH, Khang SK, et al. Tumors of the central nervous system in Korea: a multicenter study of 3221 cases. J Neurooncol 2002;56:251-259.

42. Matsutani M. Pineal germ cell tumors. Prog Neurol Surg 2009;23:76-85.

43. Pointer JN, Fonstad R, Tolar J, Spector LG, Ross JA. Incidence of intracranial germ cell tumours by race in United States, 1992-2010. J Neurooncol 2014;120:381-388.

44. Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90. J Neurol Neurosurg Psychiatry 1996;61:143-150.

45. Pobereskin LH, Chadduck JB. Incidence of brain tumours in two English counties: a population based study. J Neurol Neurosurg Psychiatr 2000;69:464-471.

46. Lönn S, Klaeboe L, Hall P, Mathiesen T, Auvinen A, Christensen HC, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer 2004;108:450-455.

47. Lee C-H, Jung K-W, Yoo H, Park S, Lee SH. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosur Soc 2010;48(2):145-152.

48. Klaeboe L, Lönn S, Scheie D, Auvinen A, Christensen HC, Feychting M, et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. Int J Cancer 2005;117:996-1001.

49. Larjavaara S, Haapasalo H, Sankila R, Helén P, Auvinen A. Is the incidence of meningiomas underestimated? A regional survey. Br J Cancer 2008;99:182-184.

50. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 2008;26(2):279-282.

Enlaces refback

Salud Pública de México es una publicación periódica electrónica, bimestral, publicada por el Instituto Nacional de Salud Pública (con domicilio en Avenida Universidad núm. 655, col. Santa María Ahuacatitlán, Cuernavaca, Morelos, C.P. 62100, teléfono 329-3000, página web,, con ISSN: 1606-7916 y Reserva de Derechos al Uso Exclusivo con número: 04-2012-071614550600-203, ambos otorgados por el Instituto Nacional del Derecho de Autor. Editor responsable: Carlos Oropeza Abúndez. Responsable de la versión electrónica: Subdirección de Comunicación Científica y Publicaciones, Avenida Universidad núm. 655, planta baja, col. Santa María Ahuacatitlán, Cuernavaca, Morelos, C.P. 62100, teléfono 329 3000. Fecha de última modificación: 7 de junio de 2018. D.R. © por el sitio: Instituto Nacional de Salud Pública.

Gestionando el conocimiento